Roivant Sciences Ltd (ROIV)
Pretax margin
| Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) (ttm) | US$ in thousands | 4,371,154 | 4,493,816 | -977,239 | -966,094 | -1,003,840 | -1,236,655 | -1,171,958 | -1,090,613 | -844,893 |
| Revenue (ttm) | US$ in thousands | 90,017 | 87,063 | 67,973 | 44,317 | 33,312 | 22,259 | 36,493 | 44,730 | 48,245 |
| Pretax margin | 4,855.92% | 5,161.57% | -1,437.69% | -2,179.96% | -3,013.45% | -5,555.75% | -3,211.46% | -2,438.21% | -1,751.26% |
March 31, 2024 calculation
Pretax margin = EBT (ttm) ÷ Revenue (ttm)
= $4,371,154K ÷ $90,017K
= 4,855.92%
The pretax margin of Roivant Sciences Ltd has shown significant fluctuations over the past nine quarters. In the most recent quarter ending March 31, 2024, the pretax margin stood at an exceptionally high 4,855.92%. This indicates that for every dollar of revenue generated, the company was able to retain a large portion as pre-tax profit.
However, it is worth noting that the pretax margin has been volatile in previous quarters, with figures ranging from as high as 5,161.57% to as low as -5,555.75%. These fluctuations suggest potential inconsistencies in the company's profitability and cost management strategies.
The negative pretax margins seen in several quarters, such as in September 2023, June 2023, and March 2023, raise concerns about the company's ability to generate sustainable profits before taxes. It is important for stakeholders to further investigate the factors driving these fluctuations to assess the company's overall financial health and stability.
Peer comparison
Mar 31, 2024